Showing results (1451-1460 of 1,497) with videos related to
Sort By:
Pageof 150
Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics|July 1, 2022
[Factors affecting phenotypes in the patients with MMACHC gene c.609G>A homozygous variant cblC type methylmalonic acidemia combined with homocysteinuria]Ruxuan He, Ruo Mo, Yao Zhang, et al.Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole coreDong-Ming Shen, Edward J Brady, Mari R Candelore, et al.Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanesThomas H Graham, Wensheng Liu, Andreas Verras, et al.Cell Metabolism|May 1, 2018
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human PrimatesDavid G McLaren, Seongah Han, Beth Ann Murphy, et al.Carcinogenesis|August 29, 2007
Evaluation of oxidative stress in a group of adolescents exposed to a high level of aflatoxin B1--a multi-center and multi-biomarker studyTao Peng, Le-Qun Li, Min-Hao Peng, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.Bioorganic & Medicinal Chemistry Letters|August 17, 2005
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonistsDong-Ming Shen, Fengqi Zhang, Edward J Brady, et al.Theranostics|December 8, 2025
Aggregation-induced emission of DNA fluorescence as a novel pan-marker of cell death, senescence and sepsis in vitro and in vivoYiling Hu, Xiaoyan Wang, Ke Lu, et al.The Journal of Clinical Endocrinology and Metabolism|May 6, 2022
Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's DiseaseZhengyuan Chen, Qi Jia, Zhaozhao Zhao, et al.Pageof 150